BioSpace News Archive

IDEAYA Biosciences, Inc. announced that it intends to offer and sell up to $80 million of shares of its common stock in an underwritten public offering.

Hillrom will host its fiscal third quarter 2021 earnings conference call and webcast on Friday, July 30, 2021, beginning at 7:30 a.m. / 8:30 a.m..

The rise in the incidence rate of ankylosing spondylitis, the elevating focus on R&D activities, and lack of approval of therapies have resulted in boosting the Ankylosing Spondylitis Drugs market.

EpimAb Biotherapeutics, today announced dose administration for the first patient in a Phase 1/2 clinical trial of EMB-02, a bispecific antibody targeting PD-1 and LAG-3, in patients with advanced solid tumors, as well as in a Phase 1/2 clinical trial of EMB-06, a bispecific antibody targeting B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3), in patients with recurrent and refractory multiple myeloma.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, announces that it will not be advancing Ifenprodil into a Phase 3 clinical study for COVID-19.

Locanabio, Inc. today announced the appointment of John P. Leonard , PhD, to chief scientific officer and Edward R. Conner , MD, to chief medical officer, effective today.

Biocept, Inc . (NASDAQ: BIOC), a leading provider of molecular diagnostic assays and services, has been awarded a South Korean Patent for its Primer-Switch technology.

Avinger, Inc. today announced the submission of a 510(k) application to the U.S. Food & Drug Administration (FDA) for a new Pantheris clinical indication for the treatment of in-stent restenosis (ISR) in the lower extremity arteries.

Extendicare Inc. announced that it plans to release its financial results for the second quarter of 2021 after market close on Thursday, August 5, 2021.

Y-mAbs Therapeutics, Inc. today announced that SciClone Pharmaceuticals (Holdings) Limited (“SciClone Pharmaceuticals”) has submitted the Biologics License Application (“BLA”) for DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory neuroblastoma.